Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lenhard

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituentJ E Cobb, S G Blanchard, E G Boswell, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moietyJ L Collins, S G Blanchard, G E Boswell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 1999
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiationJ L Oberfield, J L Collins, C P Holmes, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 10, 2010
Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadineEllen E Codd, Judith Baker, Michael R Brandt, et al.
Diabetes|July 2, 1999
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty ratK K Brown, B R Henke, S G Blanchard, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agentsB R Henke, S G Blanchard, M F Brackeen, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituentJ E Cobb, S G Blanchard, E G Boswell, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moietyJ L Collins, S G Blanchard, G E Boswell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 1999
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiationJ L Oberfield, J L Collins, C P Holmes, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 10, 2010
Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadineEllen E Codd, Judith Baker, Michael R Brandt, et al.
Diabetes|July 2, 1999
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty ratK K Brown, B R Henke, S G Blanchard, et al.
Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agentsB R Henke, S G Blanchard, M F Brackeen, et al.
Pageof 8